Evidence map›Paper›PMID 33564942›Full record

ArticleJournal of general internal medicine2021

Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.

Michael Fralick, Donald A Redelmeier, Elisabetta Patorno, Jessica M Franklin, Fahad Razak, Tara Gomes, Sebastian Schneeweiss

Open access · bronzeAbstract read
In one paragraph

Article in Journal of general internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  14. Diabetic ketoacidosis induced by a sodium-glucose cotransporter-2 inhibitor in a 28-year-old man without known diabetes.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Michael FralickDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Suite 3030, Boston, MA, 02120, USA. mike.fralick@mail.utoronto.ca.ORCID 0000-0002-2082-2445
Donald A RedelmeierICES, Toronto, ON, Canada.
Elisabetta PatornoDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Suite 3030, Boston, MA, 02120, USA.
Jessica M FranklinDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Suite 3030, Boston, MA, 02120, USA.
Fahad RazakSt Michael's Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Tara GomesICES, Toronto, ON, Canada.
Sebastian SchneeweissDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Suite 3030, Boston, MA, 02120, USA.
Brigham and Women's Hospital · USSt. Michael's Hospital · CAInstitute for Clinical Evaluative Sciences · CA

Funding

Novel Approaches to Monitor the Safety and Effectiveness of Newly Marketed Diabetes Medications in Older Adults Considering Frailty and MultimorbidityK08AG055670 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI PATORNO, ELISABETTA · 2018 to 2021
$661k
NIA NIH HHS K08 AG055670
6 · The paper itself

Abstract

introductionSodium glucose co-transporter-2 inhibitors (SGLT2) are commonly prescribed to patients with type 2 diabetes mellitus, but can increase the risk of diabetic ketoacidosis. Identifying patients prone to diabetic ketoacidosis may help mitigate this risk.

methodsWe conducted a population-based cohort study of adults initiating SGLT2 inhibitor use from 2013 through 2017. The primary objective was to identify potential predictors of diabetic ketoacidosis. Two machine-learning methods were applied to model high-dimensional pre-exposure data: gradient boosted trees and least absolute shrinkage and selection operator (LASSO) regression. We rank ordered the variables produced from LASSO by the size of their estimated coefficient (largest to smallest). With gradient boosted trees, a relative importance measure for each variable is provided rather than a coefficient. The "top variables" were identified after reviewing the distributions of the effect estimates from LASSO and gradient boosted trees to identify where there was a substantial decrease in variable importance. The identified predictors were then assessed in a logistic regression model and reported as odds ratios (ORs) with 95% confidence intervals (CIs).

resultsWe identified 111,442 adults who started SGLT2 inhibitor use. The mean age was 57 years, 44% were female, the mean hemoglobin A1C was 8.7%, and the mean creatinine was 0.89 mg/dL. During a mean follow-up of 180 days, 192 patients (0.2%, i.e., 2 per 1000) were diagnosed and hospitalized with diabetic ketoacidosis (DKA) and 475 (0.4%, i.e., 4 per 1000) were diagnosed in either an inpatient or outpatient setting. Using gradient boosted trees, the strongest predictors were prior DKA, baseline hemoglobin A1C level, baseline creatinine level, use of medications for dementia, and baseline bicarbonate level. Using LASSO regression not including laboratory test results due to missing data, the strongest predictors were prior DKA, digoxin use, use of medications for dementia, and recent hypoglycemia. The logistic regression model incorporating the variables identified from gradient boosted trees and LASSO regression suggested the following pre-exposure characteristics had the strongest association with a hospitalization for DKA: use of dementia medications (OR = 7.76, 95% CI 2.60, 23.1), prior intracranial hemorrhage (OR = 11.5, 95% CI 1.46, 91.1), a prior diagnosis of hypoglycemia (OR = 5.41, 95% CI 1.92,15.3), prior DKA (OR = 2.45, 95% CI 0.33, 18.0), digoxin use (OR = 4.00, 95% CI 1.21, 13.2), a baseline hemoglobin A1C above 10% (OR = 3.14, 95% CI 1.95, 5.06), and baseline bicarbonate below 18 mmol/L (OR 5.09, 95% CI 1.58, 16.4).

conclusionDiabetic ketoacidosis affected approximately 2 per 1000 patients starting to use an SGLT2 inhibitor. We identified both anticipated, e.g., low baseline serum bicarbonate, and unanticipated, e.g., digoxin, dementia medications, risk factors for SGLT2 inhibitor-induced DKA.

Indexed as

Diabetes Mellitus, Type 2Diabetic KetoacidosisSodium-Glucose Transporter 2 InhibitorsAdultCohort StudiesFemaleHumansMiddle AgedRisk FactorsUnited StatesSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID33564942
PMCPMC8390572
OpenAlexW3127324871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.